<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classifying asthma severity in children 5 to 11 years of age</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classifying asthma severity in children 5 to 11 years of age</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classifying asthma severity in children 5 to 11 years of age</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup> <colgroup span="5" width="18%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" colspan="2" rowspan="3">Components of severity</td> <td class="subtitle1" colspan="4">Classification of asthma severity (children 5 to 11 years of age)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2" rowspan="2">Intermittent</td> <td class="subtitle2" colspan="3">Persistent</td> </tr> <tr class="divider_bottom"> <td class="subtitle3">Mild</td> <td class="subtitle3">Moderate</td> <td class="subtitle3">Severe</td> </tr> <tr> <td class="divider_bottom" rowspan="5">Impairment</td> <td>Symptoms</td> <td>≤2 days/week</td> <td>&gt;2 days/week, but not daily</td> <td>Daily</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>≤2 times/month</td> <td>3 to 4 times/month</td> <td>&gt;1 time/week, but not nightly</td> <td>Often 7 times/week</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>≤2 days/week</td> <td>&gt;2 days/week, but not daily</td> <td>Daily</td> <td>Several times per day</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Minor limitation</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr class="divider_bottom"> <td>Lung function</td> <td> <ul> <li>Normal FEV<sub>1</sub> between exacerbations</li> <li>FEV<sub>1</sub> &gt;80% predicted</li> <li>FEV<sub>1</sub>/FVC &gt;85%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> &gt;80% predicted</li> <li>FEV<sub>1</sub>/FVC &gt;80%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> = 60 to 80% predicted</li> <li>FEV<sub>1</sub>/FVC = 75 to 80%</li> </ul> </td> <td> <ul> <li>FEV<sub>1</sub> &lt;60% predicted</li> <li>FEV<sub>1</sub>/FVC &lt;75%</li> </ul> </td> </tr> <tr> <td rowspan="4">Risk</td> <td rowspan="4"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year (refer to legend)</strong></td> <td colspan="3"><strong>≥2 in 1 year (refer to legend)</strong></td> </tr> <tr> <td colspan="4"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td colspan="4"><strong>Frequency and severity may fluctuate over time for patients in any severity category</strong></td> </tr> <tr> <td colspan="4"><strong>Relative annual risk of exacerbations may be related to FEV<sub>1</sub></strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>Classifying severity in children who are not currently taking long-term control medication.</strong> Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous 2 to 4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had ≥2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.</div><div class="graphic_footnotes">EIB: exercise-induced bronchoconstriction; FEV<sub>1</sub>: forced expiratory volume in the first second; ICU: intensive care unit.</div><div class="graphic_reference">Reproduced from: National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 07-4051NIH, National Heart, Lung, and Blood Institute, Bethesda, MD 2007.</div><div id="graphicVersion">Graphic 51579 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
